[PDF] Comparative Effectiveness Research In Heart Failure An Issue Of Heart Failure Clinics eBook
Comparative Effectiveness Research In Heart Failure An Issue Of Heart Failure Clinics Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Comparative Effectiveness Research In Heart Failure An Issue Of Heart Failure Clinics book. This book definitely worth reading, it is an incredibly well-written.
This issue of Heart Failure Clinics covers comparative-effectiveness research in heart failure. Expert authors review the most current information available about the comparative effectiveness of different treatments for heart failure, including drug treatments, cardioverter defibrillators and cardiac resynchronization therapy, as well as patient adherence. Keep up-to-the-minute with the latest developments in comparative-effectiveness research.
This issue of Heart Failure Clinics covers comparative-effectiveness research in heart failure. Expert authors review the most current information available about the comparative effectiveness of different treatments for heart failure, including drug treatments, cardioverter defibrillators and cardiac resynchronization therapy, as well as patient adherence. Keep up-to-the-minute with the latest developments in comparative-effectiveness research.
This issue of Heart Failure Clinics, guest edited by Drs. Clyde W. Yancy and R. Kannan Mutharasan, will cover Process Improvement in Heart Failure. This issue is one of four issues selected each year by our series consulting editor, Dr. Eduardo Bossone. Topics discussed in this issue will include: Approaching Process Improvement, Identifying Heart Failure Patients, Predicting High-risk Patients and High-Risk Outcomes in Heart Failure, Selecting the Correct Target for Improvement in Heart Failure Care and Improving Adherence, Empowering Patients Living with Heart Failure with Social Media and Technology, Transitioning Heart Failure Patients to Outpatient Care, Innovating Outpatient Processes of Care and Anticipating Complex Care Algorithms, Addressing Co-morbidities in Heart Failure, Systematizing Heart Failure Population Health, Defragmenting Heart Failure Care, and Adapting to the Payment Landscape.
This issue of Heart Failure Clinics is dedicated to an in-depth analysis of the conduct of clinical investigation in patients with acute decompensated heart failure (ADHF). It tackles the difficult questions involved in patient population, trial conduct, surrogate endpoints, clinical endpoints, and statistical considerations. The purpose of the issue is to provide information that will be meaningful and useful to help physicians in thinking about the design of clinical trials in this field.
This special issue of Heart Failure Clinics examines heart failure with a truly global perspective, exposing health inequities in the treatment of heart failure.
Chronic overconsumption of sugar and fat elevates plasma levels of insulin and free fatty acids, a process referred to as glucolipotoxicity. This phenomenon may lead to heart failure. This issue explores in depth the relationship between glucolipotoxicity and heart failure.
This issue of Heart Failure Clinics is devoted to atrial fibrillation in heart failure. It covers medical management and drug treatment as well as devices and ablation and aims to provide heart failure specialists with the current state of the art in handling this common problem in heart failure patients.
Agency for Health Care Research and Quality (U.S.)
Author : Agency for Health Care Research and Quality (U.S.) Publisher : Government Printing Office Page : 236 pages File Size : 49,89 MB Release : 2013-02-21 Category : Medical ISBN : 1587634236
This User’s Guide is a resource for investigators and stakeholders who develop and review observational comparative effectiveness research protocols. It explains how to (1) identify key considerations and best practices for research design; (2) build a protocol based on these standards and best practices; and (3) judge the adequacy and completeness of a protocol. Eleven chapters cover all aspects of research design, including: developing study objectives, defining and refining study questions, addressing the heterogeneity of treatment effect, characterizing exposure, selecting a comparator, defining and measuring outcomes, and identifying optimal data sources. Checklists of guidance and key considerations for protocols are provided at the end of each chapter. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews. More more information, please consult the Agency website: www.effectivehealthcare.ahrq.gov)
This issue of Heart Failure Clinics is about acute decompensated heart failure. Expert authors review the most current information available about comorbidities, management, drug therapy, and strategies to prevent a post-discharge adverse event. Keep up-to-the-minute with the latest developments in this life-threatening disorder.
Heart failure (HF) is a major public health problem and a leading cause of hospitalization and health care costs in the United States. It is the most common principal discharge diagnosis among Medicare beneficiaries and the third highest for hospital reimbursements. Up to 25 percent of patients hospitalized with HF are readmitted within 30 days. In an effort to reduce the frequency of rehospitalization of Medicare patients, in October 2012 CMS began lowering reimbursements to hospitals with excessive risk-standardized readmission rates as part of the Hospital Readmissions Reduction Program authorized by the Affordable Care Act. This policy provides incentives for hospitals to develop effective transition programs to reduce readmission rates for people with HF. In 2010, nearly 7 million Americans 18 years of age and older had an HF diagnosis; by 2030, an additional 3 million Americans will have the condition. The incidence of HF increases with age; it affects 1 of every 100 people 65 years of age and older. Coronary disease and uncontrolled hypertension are the two highest population-attributable risks for HF. Survival after HF diagnosis has improved over time. However, the death rate remains high: 50 percent of people diagnosed with HF die within 5 years after diagnosis. Among Medicare beneficiaries, more than 30 percent of patients with HF die within 1 year after hospitalization. National data show no evidence that readmission rates for HF patients have fallen during the past two decades, despite the observation that HF hospitalizations in the United States have declined by almost 30 percent during the past decade. Readmission rates vary by both geographic location and insurance coverage. The relationship between readmission rates and other important outcomes (e.g., mortality, emergency room [ER] visits) is unclear. Some data suggest that hospitals with the lowest mortality rates among patients with HF tend to have higher readmission rates. Some predict that interventions aimed at reducing readmissions may increase use of other health care services, such as ER observational visits. An assessment of the efficacy, comparative effectiveness, and harms of transitional care interventions is needed to support evidence-based policy and clinical decisionmaking. Despite advances in the quality of acute and chronic HF disease management, gaps remain in knowledge about effective interventions to support the transition of care for patients with HF.Our report focuses mainly on transitional care interventions that aim to reduce 30-day readmission and mortality rates for patients hospitalized with HF. We also include readmissions measured over 3 to 6 months because these are common, costly, and potentially preventable. We examine several related issues, including other health care use (e.g., ER visits), quality of life, and potential harms such as increased caregiver burden. We include these outcomes because they may provide information on the unintended consequences of interventions aimed at preventing readmissions.